AU
AUTL.US Autolus Therapeutics Ltd
- Market cap
- USD 311M
- P/E
- -
- P/B
- 11.61x
- ROE
- -806.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is AUTL.US undervalued?
Graham numberThe Graham number of Autolus Therapeutics Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Autolus Therapeutics Ltd fundamental analysis
No fundamental analysis for Autolus Therapeutics Ltd yet.
Autolus Therapeutics Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Autolus Therapeutics Ltd
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multi…
Full company profileAutolus Therapeutics Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Autolus Therapeutics Ltd annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.21M | 1.69M | 1.05M | 2.91M | 1.72M | 1.51M | 6.19M | 1.70M | 10.1M | 75.6M | 151M |
| Gross Profit | 734K | 684K | -47.3M | -103M | -133M | 1.51M | 6.19M | 1.70M | -131M | -21.0M | 66.9M |
| Operating Income | -14.4M | -23.4M | -57.5M | -248M | -303M | -140M | -143M | -180M | -241M | -281M | -196M |
| EBITDA | -13.9M | -22.4M | -50.3M | -137M | -162M | -132M | -132M | -157M | -233M | -250M | -175M |
| Net Income | -12.6M | -19.7M | -31.1M | -124M | -142M | -142M | -149M | -208M | -221M | -288M | -221M |
| EPS | -0.91 | -1.43 | -0.99 | -2.88 | -2.76 | -1.97 | -1.57 | -1.20 | -0.86 | -1.08 | -0.83 |
| Balance Sheet | |||||||||||
| Total Assets | 34.2M | 149M | 218M | 304M | 294M | 406M | 490M | 375M | 783M | 589M | 523M |
| Total Liabilities | 3.49M | 6.06M | 12.5M | 48.7M | 84.2M | 92.2M | 192M | 264M | 355M | 411M | 496M |
| Shareholders' Equity | 30.7M | 143M | 205M | 255M | 210M | 313M | 299M | 111M | 427M | 178M | 27.4M |
| Cash & Short-term Investments | 28.1M | 137M | 189M | 211M | 154M | 310M | 382M | 240M | 588M | 301M | 248M |
| Total Debt | 188K | 265K | 221K | 26.2M | 54.2M | 68.0M | 24.3M | 53.0M | 52.6M | 352M | 148M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -9.85M | -16.4M | -25.8M | -101M | -118M | -118M | -112M | -146M | -206M | -284M | -145M |
| Capital Expenditure | 1.86M | 2.88M | 8.77M | 18.7M | 14.7M | 8.86M | 10.8M | 11.0M | 34.8M | 27.1M | 6.46M |
| Free Cash Flow | -11.7M | -19.2M | -34.6M | -120M | -132M | -127M | -123M | -157M | -241M | -311M | -152M |
| Ratios | |||||||||||
| ROE | -40.9% | -13.8% | -15.2% | -48.6% | -67.7% | -45.4% | -49.8% | -186.9% | -51.6% | -161.8% | -806.9% |
| ROA | -36.7% | -13.3% | -14.3% | -40.8% | -48.3% | -35.0% | -30.4% | -55.5% | -28.2% | -48.9% | -42.3% |
| Net Profit Margin | -1,035.5% | -1,165.2% | -2,976.5% | -4,258.9% | -8,285.4% | -9,429.1% | -2,403.0% | -12,272.3% | -2,180.5% | -381.4% | -146.5% |
| Debt to Equity | 0.01x | 0.00x | 0.00x | 0.10x | 0.26x | 0.22x | 0.08x | 0.48x | 0.12x | 1.97x | 5.40x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Autolus Therapeutics Ltd dividends
Autolus Therapeutics Ltd has not paid dividends in the last 9 fiscal years.
Who owns Autolus Therapeutics Ltd
- Insiders 18.55%
- Institutions 55.73%
- Public & others 25.72%
- Shares outstanding 266M
- Free float 103M
Top funds holding AUTL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| International Biotechnology Ord | 6.53M | 2.45% | -9.51% | Aug 2026 |
| AXA Framlington Health Fund - R Income | 3.36M | 1.26% | 0.00% | Sep 2026 |
| iShares Biotechnology ETF | 1.34M | 0.50% | -0.19% | Oct 2026 |
| JPM Thmtcs Gentc Thrps C2 dist USD | 873K | 0.33% | -0.83% | Sep 2026 |
| MGTS Sentinel Navigator B Acc | 287K | 0.11% | 0.00% | Jul 2026 |
| Ashburton Global Equity Growth D USD | 284K | 0.11% | 0.00% | Sep 2026 |
| Tema Oncology ETF | 281K | 0.11% | 0.00% | Oct 2026 |
| ERSTE STOCK BIOTEC EUR R01 A | 195K | 0.07% | 0.00% | Aug 2026 |
| iShares Nasdaq US Biotech ETF USD Acc | 180K | 0.07% | +0.21% | Oct 2026 |
| MGTS Downing Diversified Opps F GBP Acc | 180K | 0.07% | 0.00% | Jul 2026 |
| SVS Aubrey Citadel Fund A GBP Acc | 180K | 0.07% | +38.46% | Apr 2026 |
| State Street® SPDR® S&P® Intl Sm Cp ETF | 102K | 0.04% | 0.00% | Oct 2026 |
| Galileo - Biotech Innovation Fund S USD | 100K | 0.04% | 0.00% | Apr 2026 |
| Invesco NASDAQ Future Gen 200 ETF | 49.8K | 0.02% | +1.92% | Oct 2026 |
| Pharus Sicav Asian Value Niches Q | 33.0K | 0.01% | +200.00% | Sep 2026 |
| China Universal NASDAQ Bio-Tch ETF(QDII) | 31.9K | 0.01% | -2.33% | Jun 2026 |
| ActivePassive International Equity ETF | 31.7K | 0.01% | 0.00% | Oct 2026 |
| HealthInvest S&M Cap Healthcare C | 23.1K | 0.01% | 0.00% | Jan 2026 |
| Invesco Nasdaq Biotechnology ETF | 15.4K | 0.01% | 0.00% | Oct 2026 |
| Fidelity Nasdaq Composite Index | 13.4K | 0.01% | -89.71% | Aug 2026 |
Top institutions holding AUTL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Mak Capital One LLC | 33.6M | 12.63% | 0.00% | Jun 2026 |
| Blackstone Inc | 20.5M | 7.70% | 0.00% | Jun 2026 |
| Syncona Portfolio Ltd. | 16.6M | 6.25% | 0.00% | Jun 2026 |
| Armistice Capital, LLC | 15.0M | 5.64% | -5.06% | Jun 2026 |
| Polygon Management Ltd | 9.50M | 3.57% | 0.00% | Jun 2026 |
| Schroder Investment Management Group | 7.83M | 2.94% | -17.45% | Jun 2026 |
| Frazier Life Sciences Management, L.P. | 4.45M | 1.67% | 0.00% | Jun 2026 |
| BNP Paribas Investment Partners SA | 3.36M | 1.26% | 0.00% | Jun 2026 |
| LAURION CAPITAL MANAGEMENT LP | 3.32M | 1.25% | 0.00% | Jun 2026 |
| Renaissance Technologies Corp | 1.98M | 0.75% | -13.69% | Jun 2026 |
| Bank of America Corp | 1.61M | 0.60% | -12.99% | Jun 2026 |
| BlackRock Inc | 1.60M | 0.60% | +8.29% | Jun 2026 |
| UBS Group AG | 1.52M | 0.57% | +16.18% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 1.26M | 0.47% | +33.87% | Jun 2026 |
| Millennium Management LLC | 1.22M | 0.46% | +498.27% | Jun 2026 |
| Cetera Investment Advisers | 1.16M | 0.43% | +2.50% | Jun 2026 |
| Balyasny Asset Management LLC | 973K | 0.37% | +0.11% | Jun 2026 |
| JPMorgan Chase & Co | 913K | 0.34% | -2.37% | Jun 2026 |
| Alphabet Inc | 698K | 0.26% | 0.00% | Jun 2026 |
| Citadel Advisors Llc | 696K | 0.26% | +51.48% | Jun 2026 |
Autolus Therapeutics Ltd company profile
- Company name
- Autolus Therapeutics Ltd
- Ticker
- AUTL.US
- Exchange
- USA Stocks
- Listed since
- Jun 22, 2018
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 752
- Fiscal year end
- December
- Address
- The Mediaworks, London, United Kingdom, W12 7FP
- Phone
- 44 20 3829 6230
- Website
- autolus.com
About Autolus Therapeutics Ltd
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor. It also develops obe-cel, which is in phase 1 to treat systemic lupus erythematosus, progressive multiple sclerosis, B-NHL and CLL, and CNS lymphoma; obe-cel, which is in phase 2 to treat pediatric B-ALL and lupus nephritis; AUTO1/22 to treat pediatric B-ALL, which is phase 1; AUTO8, which is in phase 1 to treat multiple myeloma and light chain amyloidosis; AUTO4/5, which is in preclinical stage to treat peripheral TCL; AUTO6NG, which is in phase 1 to treat neuroblastoma; and AUTO9, which is in preclinical stage to treat acute myeloid leukemia. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Autolus Therapeutics Ltd management
10- Dr. Christian Martin Itin Ph.D.CEO & Director · born 1964
- Dr. Martin Pule M.D., MBBSFounder, Senior VP & Chief Scientific Officer · born 1972
- Mr. Robert F. DolskiSenior VP & CFO · born 1971
- Mr. Christopher VannSenior VP & COO · born 1965
- Mr. Patrick McIlvennySenior VP of Finance, Chief Accounting Officer & Principal Accounting Officer · born 1980
- Ms. Miranda NevilleSenior VP & Chief Technology Officer · born 1975
- Mr. Alex DriggsSenior VP of Legal Affairs & General Counsel and Secretary · born 1976
- Mr. Alexander SwanSenior VP & Chief Human Resources Officer · born 1965
- Dr. Christopher Williams Ph.D.Senior VP & Chief Business Development Officer · born 1980
- Dr. Matthias Will M.D.Senior VP & Chief Development Officer · born 1973